Novo Nordisk CEO spies new pharmaceutical sales model

Lars Fruergaard Jørgensen, CEO of Novo Nordisk, predicts that a new model for pharmaceutical sales will emerge in the long term – a model that can simplify the distribution and pricing of drugs, he tells Danish media Børsen.

Photo: Stine Bidstrup/Ritzau Scanpix

The collaboration between public and private pharmaceutical companies, which has been happening during the pandemic, can form the basis of a new business model for pharmaceutical sales in the long term, the CEO of Novo Nordisk Lars Fruergaard Jørgensen tells Danish financial daily Børsen.

He highlights that the way drugs are sold and distributed today can be simplified.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs